New optimism for pharma market prospects in Evaluate’s “World Preview 2014, Outlook to 2020” report. This graphic highlights key data from the market intelligence firm’s annual state of the industry report, which recently launched at BIO.
This much improved growth outlook comes as welcome news after two years of actual sales stagnation. While the patent cliff is now but a distant memory, a new debate over drug pricing is stirring up controversy. This will only intensify as the industry continues to shift away from primary care and new technology waves offer innovative products that potentially take costs out of healthcare, says Paul Hills, report author and Evaluate’s head of operations.